1,2-dimethyl-1H-imidazo<4,5-b>pyridine | 34452-84-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 1,2-dimethyl-1H-imidazo<4,5-b>pyridine
• 英文别名: 1,2-dimethyl-1H-imidazo[4,5-b]pyridine；1,2-Dimethyl-1H-imidazo<4,5-b>pyridin；1,2-Dimethyl-1H-imidazo[4,5-b]pyridine；1,2-dimethylimidazo[4,5-b]pyridine
• CAS: 34452-84-1
• 化学式: C₈H₉N₃
• 分子量: 147.18
• InChiKey: NAVDBUWCGQBJMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,2-dimethyl-1H-imidazo<4,5-b>pyridine 在 potassium permanganate 、 氯化亚砜 、 sodium carbonate 作用下， 以 水 为溶剂， 反应 6.0h， 生成 1-methyl-1H-2-imidazo<4,5-b>pyridinecarboxylic acid methyl ester
  参考文献：
  名称：

  Bukowski; Janowiec, Pharmazie, 1996, vol. 51, # 1, p. 27 - 30

  摘要：

  DOI：
• 作为产物：
  描述：

  N3-甲基吡啶-2,3-二胺 在 盐酸 作用下， 以 甲醇 为溶剂， 反应 0.33h， 生成 1,2-dimethyl-1H-imidazo<4,5-b>pyridine
  参考文献：
  名称：

  Bukowski; Janowiec, Pharmazie, 1990, vol. 45, # 12, p. 904 - 907

  摘要：

  DOI：

文献信息

• Organic compounds
  申请人：Glatthar Ralf

  公开号：US20090105266A1

  公开（公告）日：2009-04-23

  The present invention relates to novel benzimidazole derivatives, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them, wherein the compounds have the formula (I): in which the substitutents are as defined in claim 1 and salts, solvates, hydrates and N-oxides thereof.

  本发明涉及新型苯并咪唑衍生物，其制备，其用作药物以及含有它们的药物组合物，其中化合物具有以下结构式（I）： 其中取代基如权利要求1中所定义，并且其盐、溶剂合物、水合物和N-氧化物。
• Halogenation of 2-Unsubstituted and 2-Methylimidazo[4,5-b]pyridine Derivatives
  作者：Yu. M. Yutilov、Kh. Ya. Lopatinskaya、N. N. Smolyar、S. V. Gres’ko

  DOI：10.1007/s11178-005-0186-y

  日期：2005.3

  Halogenation of 2-unsubstituted and 2-methylimidazo[4,5-b]pyridines and their N-methyl derivatives with bromine and chlorine in acetic acid takes different pathways, depending on the acetic acid concentration. The bromination in 50% aqueous acetic acid gives only 6-bromoimidazo[4,5-b]pyridines; bromination and chlorination of 2-unsubstituted imidazo[4,5-b]pyridines in glacial acetic acid leads to 5,6-dibromo(dichloro)imidazo[4,5-b]pyridin-2-ones, and bromination of 2-methylimidazo[4,5-b]pyridines in glacial acetic acid involves both the pyridine ring and the 2-methyl group to afford the corresponding 6-bromo-2-tribromomethylimidazo[4,5-b]pyridines.

  在乙酸中用溴和氯对 2-未取代的和 2-甲基咪唑并[4,5-b]吡啶及其 N-甲基衍生物进行卤化，根据乙酸浓度的不同，卤化途径也不同。在 50% 的乙酸水溶液中进行溴化反应只能得到 6-溴咪唑并[4,5-b]吡啶；在冰醋酸中对 2-未取代的咪唑并[4,5-b]吡啶进行溴化和氯化反应，可生成 5,6-二溴（二氯）咪唑并[4,5-b]吡啶-2-酮；在冰醋酸中对 2-甲基咪唑并[4,5-b]吡啶进行溴化反应，可生成 2-甲基咪唑并[4,5-b]吡啶-2-酮、2-甲基咪唑并[4,5-b]吡啶在冰乙酸中的溴化反应涉及吡啶环和 2-甲基，从而得到相应的 6-溴-2-三溴甲基咪唑并[4,5-b]吡啶。
• Organic Electroluminescent Materials and Devices
  申请人：Universal Display Corporation

  公开号：US20170237018A1

  公开（公告）日：2017-08-17

  This invention relates to the development of heterocyclic materials for use as blue phosphorescent materials in OLED devices. The materials are based on a pair of 5 -membered aromatic or psuedoaromatic rings bonded to one another and complexed to a transition metal. The materials were determined computationally to have appropriate triplet energies for use as blue emitters and to possess sufficient chemical stability for use in devices.

  本发明涉及开发杂环材料，用作OLED设备中的蓝色荧光材料。该材料基于两个相互连接的5元芳香或伪芳香环，并与过渡金属配合。计算确定该材料具有适当的三重能级以用作蓝色发射体，并具有足够的化学稳定性以用于设备。
• Heteroarylphenylurea Derivative
  申请人：Oikawa Nobuhiro

  公开号：US20080119466A1

  公开（公告）日：2008-05-22

  The present invention provides a compound represented by the formula (1): wherein R 1 , R 2 and R 5 are each independently selected from a hydrogen atom, a halogen atom, a C 1 -C 6 alkyl is substituted with a halogen atom and the like; R 3 and R 4 are each independently selected from a hydrogen atom, a halogen atom, a substituted C 1 -C 6 alkyl group and the like; R 6 and R 7 are each independently selected from a hydrogen atom and a halogen atom; Z 1 and Z 2 are each independently selected from a hydrogen atom, a hydroxyl group and —O(CHR 11 )OC(═O)R 12 ; Q is a group of the formula: (wherein G 1 is C—Y 2 or N; a ring A is a benzene ring or a 5- to 6-membered unsaturated heterocycle) a pharmaceutically acceptable salt thereof or a prodrug thereof.

  本发明提供了一种由式（1）表示的化合物：其中，R1、R2和R5分别独立地选自氢原子、卤原子、C1-C6烷基被卤原子等取代基；R3和R4分别独立地选自氢原子、卤原子、取代的C1-C6烷基等基团；R6和R7分别独立地选自氢原子和卤原子；Z1和Z2分别独立地选自氢原子、羟基和—O（CHR11）OC（═O）R12；Q是下式的基团：（其中，G1是C—Y2或N；环A是苯环或5-至6-成员的不饱和杂环）；其药学上可接受的盐或前药。
• FACTOR XA INHIBITORS
  申请人：Zhu Bing-Yan

  公开号：US20090298806A1

  公开（公告）日：2009-12-03

  The present invention is directed to compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.

  本发明涉及由公式I表示的化合物及其药学上可接受的盐、溶剂化合物、水合物和前药，这些化合物是凝血因子Xa的抑制剂。本发明还涉及制备这些化合物所使用的中间体，含有这些化合物的药物组合物，预防或治疗一系列由不良血栓形成表征的疾病的方法，以及抑制血样的凝血的方法。